INBX jumps after ozekibart colorectal cancer update and regulatory progress

By: Quiver PriceTracker

Posted: 5 days ago / April 22, 2026 2:52 p.m. UTC

INBX

Inhibrx Biosciences, Inc. (INBX) is up 26.7% today. Here is some analysis on what might have caused this price movement.

Analysis: Shares appear to be reacting to new clinical and regulatory updates for ozekibart (INBRX-109), including encouraging late-line colorectal cancer data and confirmation of a recent BLA submission in chondrosarcoma. For a development-stage biotech, signs of efficacy plus clearer regulatory timelines can quickly shift investor expectations.

Details:

An April 21, 2026 Form 8-K disclosed updated interim Phase 1/2 results for ozekibart plus FOLFIRI in heavily pretreated, unresectable colorectal cancer.

The update cited a 20% objective response rate in 45 evaluable patients, versus historically low response rates for available late-line options.

The company also highlighted a median progression-free survival of 5.5 months and an overall disease control rate of 87% in the evaluable population.

The filing and accompanying press release noted the company submitted a Biologics License Application to the FDA for ozekibart in conventional chondrosarcoma in April 2026, and hosted a webcast to discuss the data.

Sources:

U.S. Securities and Exchange Commission, Inhibrx Biosciences (press release)

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive INBX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$INBX Hedge Fund Activity

We have seen 80 institutional investors add shares of $INBX stock to their portfolio, and 45 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MORGAN STANLEY added 724,872 shares (+163.7%) to their portfolio in Q4 2025, for an estimated $57,264,888
CAPITAL RESEARCH GLOBAL INVESTORS added 421,575 shares (+inf%) to their portfolio in Q4 2025, for an estimated $33,304,425
VIKING GLOBAL INVESTORS LP removed 350,000 shares (-19.6%) from their portfolio in Q4 2025, for an estimated $27,650,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 297,116 shares (+inf%) to their portfolio in Q4 2025, for an estimated $23,472,164
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND added 264,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,856,000
WOODLINE PARTNERS LP removed 197,111 shares (-58.6%) from their portfolio in Q4 2025, for an estimated $15,571,769
STATE STREET CORP added 171,038 shares (+83.9%) to their portfolio in Q4 2025, for an estimated $13,512,002

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.